This could be because, despite the fact that both drugs are monoclonal antibodies that target the EGFR, their affinities for the receptor differ; panitumumab may have a higher affinity and be more effective at blocking the receptor, which could have a greater impact on magnesium reabsorption and enhance the risk of hypomagnesemia. This evidence concerns the gene EGFR and familial primary hypomagnesemia.